Molecular Partners AG (OTCMKTS:MLLCF – Get Free Report) shares shot up 4.3% on Tuesday . The company traded as high as $3.60 and last traded at $3.60. 600 shares traded hands during trading, an increase of 20% from the average session volume of 500 shares. The stock had previously closed at $3.45.
Molecular Partners Trading Up 4.3%
The stock’s fifty day moving average is $3.71 and its two-hundred day moving average is $4.04.
About Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Read More
- Five stocks we like better than Molecular Partners
- The Risks of Owning Bonds
- The Drone Arms Race: From Battlefield to Balance Sheet
- Energy and Oil Stocks Explained
- Why Wall Street Is Backing These 3 Comeback Stocks
- What is a Stock Market Index and How Do You Use Them?
- Intel’s Breakout Quarter: More Than a Beat, It’s a Declaration
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
